Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.4% – Here’s Why

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s share price dropped 6.4% during trading on Monday . The company traded as low as $63.50 and last traded at $63.7430. Approximately 317,916 shares were traded during trading, a decline of 47% from the average daily volume of 595,805 shares. The stock had previously closed at $68.12.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. Citizens Jmp raised their price objective on shares of Structure Therapeutics from $87.00 to $120.00 and gave the stock a “market outperform” rating in a report on Friday, December 12th. Stifel Nicolaus boosted their target price on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Finally, Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $99.11.

Structure Therapeutics Trading Up 4.8%

The company has a market cap of $4.02 billion, a PE ratio of -54.30 and a beta of -2.05. The business’s 50 day moving average is $49.11 and its two-hundred day moving average is $31.41.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). As a group, equities research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC raised its position in shares of Structure Therapeutics by 3,326.0% during the first quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company’s stock valued at $949,000 after buying an additional 53,216 shares during the last quarter. Zimmer Partners LP grew its stake in Structure Therapeutics by 77.1% during the first quarter. Zimmer Partners LP now owns 100,776 shares of the company’s stock valued at $1,744,000 after acquiring an additional 43,876 shares in the last quarter. Parallel Advisors LLC purchased a new position in Structure Therapeutics during the second quarter valued at $171,000. Exchange Traded Concepts LLC increased its holdings in Structure Therapeutics by 58.6% in the 2nd quarter. Exchange Traded Concepts LLC now owns 61,732 shares of the company’s stock valued at $1,280,000 after acquiring an additional 22,809 shares during the last quarter. Finally, Signaturefd LLC lifted its stake in Structure Therapeutics by 6,550.0% in the 2nd quarter. Signaturefd LLC now owns 6,650 shares of the company’s stock worth $138,000 after purchasing an additional 6,550 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.